Megan Huizenga - Publications

2014- Pharmacology  Georgetown University, Washington, DC 

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Culjat M, Huizenga MN, Forcelli PA. Age-dependent anticonvulsant actions of perampanel and brivaracetam in the methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) model of seizures in developing rats. Pharmacological Reports : Pr. PMID 33210244 DOI: 10.1007/s43440-020-00189-w  1
2019 Huizenga MN, Sepulveda-Rodriguez A, Forcelli PA. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 148: 189-198. PMID 30633929 DOI: 10.1016/j.neuropharm.2019.01.002  1
2018 Huizenga MN, Forcelli PA. Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats. Neurotoxicity Research. PMID 30141144 DOI: 10.1007/s12640-018-9944-9  1
2017 Queenan BN, Dunn RL, Santos VR, Feng Y, Huizenga MN, Hammack RJ, Vicini S, Forcelli PA, Pak DTS. Kappa opioid receptors regulate hippocampal synaptic homeostasis and epileptogenesis. Epilepsia. PMID 29114861 DOI: 10.1111/epi.13941  1
2017 Huizenga MN, Wicker E, Beck VC, Forcelli PA. Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats. Epilepsia. PMID 28691158 DOI: 10.1111/epi.13842  1
Show low-probability matches.